Compare GSK plc (GSK) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lamb Weston Holdings Inc — how do they compare? GSK plc trades at $52.6 (market cap $101.34B), while Lamb Weston Holdings Inc trades at $46.66 (market cap $6.29B). The key difference: GSK plc is far larger — about 16.1× Lamb Weston Holdings Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LW | |
|---|---|---|
Market Cap | $101.34B | $6.29B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $66.57 |
52-Week Low | $36.20 | $38.48 |
Enterprise Value | $121.95B | $10.25B |
Dividend Yield | 3.49% | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Lamb Weston (LW) trades at $46.74, up 0.52% today, near the analyst consensus price target of $49.33. The stock shows a neutral technical stance with support at $45 and resistance at $47. Recent quarters have consistently beaten EPS estimates, with Q2 2026 results expected soon. Revenue remains stable at $6.45B in 2025, though net income declined to $357M. The company's 'Focus to Win' strategy is gaining traction, supported by cost savings and volume growth in North America.
Outlook is cautiously optimistic with potential upside to price targets, but risks include margin pressure, a pending class action lawsuit, and high debt levels. Analyst sentiment is mixed with 35% buy ratings. Earnings on July 24, 2026, will be critical for confirming the turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
